SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 127.76 |
| Enterprise Value ($M) | n/a |
| Book Value ($M) | 358.45 |
| Book Value / Share | 2.68 |
| Price / Book | n/a |
| NCAV ($M) | 110.74 |
| NCAV / Share | 0.83 |
| Price / NCAV | n/a |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.14 |
| Return on Assets (ROA) | -0.16 |
| Return on Equity (ROE) | -0.19 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.85 |
| Current Ratio | 3.36 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 231.49 |
| Assets | 479.21 |
| Liabilities | 120.75 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 159.84 |
| Operating Income | -35.67 |
| Net Income | -45.44 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 3.87 |
| Cash from Investing | -38.77 |
| Cash from Financing | 107.78 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D/A | BT DE Investments Inc. | 30.00 | 23.22 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 54,709 | 192,729 | 28.39 | |
| 105,580 | 568,418 | 18.57 | |
| 206,239 | 548,230 | 37.62 | |
| 187,724 | 828,262 | 22.66 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| NUVL – Nuvalent, Inc. | NVAX – Novavax, Inc. |
| NXTC – NextCure, Inc. | OLMA – Olema Pharmaceuticals, Inc. |
| OPK – OPKO Health, Inc. |
Financial data and stock pages provided by
Fintel.io